Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects
A Randomized, Double-blind, Placebo-controlled, Single-center, Phase I, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects
Sponsor: MonitorCRO
This PHASE1 trial investigates Healthy and is currently completed. MonitorCRO leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 6 earlier versions
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE1
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
May 2019 — Nov 2019 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE1
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — May 2017 [monthly]
Recruiting PHASE1
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MonitorCRO
- R-Pharm
For direct contact, visit the study record on ClinicalTrials.gov .